Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes--the EURODIAB Prospective Complications Study
M T Schram, N Chaturvedi, C G Schalkwijk, J H Fuller, C D A Stehouwer, EURODIAB Prospective Complications Study Group, M T Schram, N Chaturvedi, C G Schalkwijk, J H Fuller, C D A Stehouwer, EURODIAB Prospective Complications Study Group
Abstract
Aims/hypothesis: The pathogenesis of vascular complications in type 1 diabetes is poorly understood, but may involve chronic, low-grade inflammation. We investigated the association of markers of inflammation with vascular complications in type 1 diabetes.
Methods: A cross-sectional nested case-control study of the follow-up data of the EURODIAB Prospective Complications Study. This study included 543 individuals (278 men) with type 1 diabetes diagnosed at <36 years of age. Cases (n=348) had complications of diabetes, controls (n=195) had no complications.
Results: C-reactive protein, interleukin-6 and tumour necrosis factor-alpha levels, which were combined in an inflammatory marker Z-score, were associated with albuminuria, retinopathy and cardiovascular disease. Calculated means (95% confidence intervals) of the marker Z-score were -0.15 (-0.22 to -0.07), 0.10 (-0.05 to 0.25), and 0.28 (0.15 to 0.41), p for trend <0.0001, in individuals with normo-, micro- and macroalbuminuria; -0.23 (-0.33 to -0.13), 0.14 (0.02 to 0.25) and 0.20 (0.07 to 0.32), p for trend <0.0001, in individuals with no, non-proliferative and proliferative retinopathy; and -0.28 (-0.39 to -0.18) and 0.06 (-0.08 to 0.20), p<0.001, in individuals without and with cardiovascular disease. Per 1 SD increase of the inflammatory marker Z-score, GFR decreased by -4.6 (-6.6 to -2.6) ml per min per 1.73 m(2) (p<0.001).
Conclusions/interpretation: We have shown that markers of inflammation are strongly and independently associated with microvascular complications and cardiovascular disease in type 1 diabetes. These data suggest that strategies to decrease inflammatory activity may help to prevent the development of vascular complications in type 1 diabetes.
References
- Diabetes. 1995 Jun;44(6):603-7
- Invest Ophthalmol Vis Sci. 2001 Jun;42(7):1586-91
- Diabetologia. 1994 Mar;37(3):278-85
- Diabetologia. 2001 Jan;44(1):108-14
- Diabetologia. 1999 Mar;42(3):351-7
- Thromb Haemost. 1998 Jul;80(1):52-7
- Lab Invest. 1994 Jun;70(6):850-61
- J Clin Invest. 1995 Sep;96(3):1395-403
- Am J Physiol Cell Physiol. 2001 May;280(5):C1057-65
- Prog Retin Eye Res. 1999 Jul;18(4):511-27
- Am J Cardiol. 1998 Dec 17;82(12A):67U-73U; discussion 85U-86U
- Diabetologia. 1995 Apr;38(4):437-44
- Diabetes Care. 2003 Jul;26(7):2165-73
- J Am Soc Nephrol. 2000 Apr;11(4):669-83
- J Clin Endocrinol Metab. 1990 Oct;71(4):1008-15
- Crit Care Med. 2000 Aug;28(8):3002-8
- Diabetologia. 1996 Jun;39(6):739-44
- Nephrol Dial Transplant. 2004 Mar;19(3):631-6
- Acta Diabetol. 1997 Mar;34(1):33-8
- Kidney Int. 1995 Oct;48(4):1158-66
- Diabetes Care. 2001 Feb;24(2):284-9
- Kidney Int. 2001 Jul;60(1):219-27
- Front Biosci. 2001 Oct 01;6:D1151-60
- Kidney Int. 2003 Jan;63(1):209-16
- N Engl J Med. 1999 Jan 14;340(2):115-26
- Curr Eye Res. 1995 Nov;14(11):1045-53
- Atherosclerosis. 2000 Feb;148(2):209-14
- N Engl J Med. 1998 Nov 12;339(20):1448-56
- Diabetes Care. 1993 May;16(5):689-94
- Diabetes. 1999 Jan;48(1):1-9
- J Am Soc Nephrol. 1998 Sep;9(9):1681-8
- Diabetes Care. 1996 Jul;19(7):689-97
- N Engl J Med. 2000 Mar 23;342(12):836-43
- Diabetes Care. 2001 Dec;24(12):2071-7
- Diabetes. 2002 Apr;51(4):1157-65
- Cardiovasc Res. 1998 Mar;37(3):586-600
- FASEB J. 2002 Mar;16(3):438-40
- Biol Pharm Bull. 1998 Oct;21(10 ):1005-8
Source: PubMed